Morningstar - Imperial Oil Limited (IMO.) We Are Lowering Our Syncrude Production Forecast; We Still See 25% Upside in Imperial Oil

Report

Morningstar

Joe Gemino

EUR 100.00 For Business Accounts Only

We Are Lowering Our Syncrude Production Forecast; We Still See 25% Upside in Imperial Oil

On the news of Suncorâ€™s Syncrude production guidance update, we are lowering our Syncrude production forecast for Imperial Oil by 5,000 barrels of oil per day. Accordingly, we are slightly lowering our fair value estimate for Imperial to $34 (CAD 44) per share from our previous estimate of $35 (CAD 45). Despite the lowered fair value estimate, we still see 25% upside in the stock. Imperial stands at the head of its class in solvent-assisted technology development. However, its growth projects ar...

14/03/2018 13 EN

Underlying

Imperial Oil Limited

Imperial Oil is an integrated oil company. Co. is active in all phases of the petroleum industry in Canada, including the exploration for, and production and sale of, crude oil and natural gas. In Canada, Co. is a producer of crude oil, natural gas and petroleum refiner and a marketer of petroleum products. Co. is also a producer of petrochemicals. As of Dec 31 2017, Co. had 1.57 billion barrels of oil-equivalent basis of net proved reserves, which consisted of 44.0 million barrels of liquids, 641.00 billion cubic feet of natural gas, 473.0 million barrels of synthetic oil, and 946.0 million barrels of bitumen.

See profile

CA4530384086 Toronto Stock Exchange Canada

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Joe Gemino

Other Reports on these Companies

SmartInsider

Imperial Oil Ltd: 1 director

A director at Imperial Oil Ltd bought 5,200 shares at 67.790USD and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

Free Trial

December 16, 2024 December 16, 2024 1 EN

Vermilion Research

Vermilion Int'l Compass: Global Equity Strategy

Buys Within Global Energy, Health Care, and Utilities Global growth stocks that have significantly outperformed since the October 2023 lows are starting to pull back, and we believe a continued pause/pullback is likely in these growth areas. Meanwhile, we are seeing a clear shift into value and defensives, and we recommend adding exposure to these areas. This type of Sector rotation is common during bull markets, as various areas of the market get their turn to shine. Reasons We Remain Bullish on Global Equities. Despite recommending adding exposure to defensives, we are not getting bearish....

EUR 42.66

January 8, 2024 January 8, 2024 1 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

Pause/Pullback Continues But Oversold Bounce Likely Support levels discussed in our 8/8/23 Compass broke, leading to a change in character and a deeper pullback. Supports we were watching included the 50-day MA and 4460-4475 on the S&P 500, $371.50 on the Nasdaq 100 (QQQ), and $190-193 on the Russell 2000 (IWM); as long as these indexes are below these levels, we believe the pause/pullback that we discussed in our 8/15/23 Compass is likely to continue. Longer-term support on the S&P 500 is at 4300-4325 (nearly hit on Friday) and 4200, and we will remain constructive as long as these supports ...

EUR 42.66

August 22, 2023 August 22, 2023 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

We Are Lowering Our Syncrude Production Forecast; We Still See 25% Upside in Imperial Oil

Imperial Oil Ltd: 1 director

Vermilion Int'l Compass: Global Equity Strategy

Vermilion Compass: Weekly Equity Strategy

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe